

# **Navana Pharmaceuticals PLC.**

**Financial Statements (Un-audited) for  
Second Quarter (Q2), FY 2024-25**

***Period: 1<sup>st</sup> July - 31<sup>th</sup> December 2024***



**Navana Pharmaceuticals PLC.**  
**Statement of Financial Position (Un-audited)**  
**As at 31 December 2024**


(Amount in BDT)

Particulars	Notes	As at	
		31-Dec-2024	30-Jun-2024
<b>Assets</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	3.00	4,997,974,408	4,650,941,337
Intangible Asset	3.01	220,000	330,000
Capital Work in Progress	4.00	546,570,161	931,717,844
Right-of-Use Asset	5.00	145,774,909	163,404,672
Investment in Marketable Securities (Fair Value)	6.00	41,058,755	76,920,238
<b>Total Non-Current Assets</b>		<b>5,731,598,233</b>	<b>5,823,314,091</b>
<b>Current Assets:</b>			
Inventories	7.00	1,525,390,572	1,283,188,710
Trade and Other Receivables	8.00	1,080,806,310	1,020,129,897
Advances, Deposits and Prepayments	9.00	2,031,924,349	2,151,093,999
Goods In Transit	10.00	714,849,852	758,207,036
Cash and Cash Equivalents	11.00	282,567,702	267,770,086
<b>Total Current Assets</b>		<b>5,635,538,785</b>	<b>5,480,389,728</b>
<b>Total Assets</b>		<b>11,367,137,018</b>	<b>11,303,703,819</b>
<b>Equity And Liabilities</b>			
<b>Equity:</b>			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium		448,170,069	448,170,069
Revaluation Reserve	13.00	1,848,295,335	1,848,295,335
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(141,676,173)	(123,143,306)
Retained Earnings		902,014,254	708,021,144
<b>Total Equity:</b>		<b>4,736,555,803</b>	<b>4,561,095,560</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities:</b>			
Loan from Directors	14.00	30,000,000	30,000,000
Lease Liabilities	15.01	54,525,758	64,500,095
Long Term Loan	16.01	155,361,175	115,319,266
Bond		80,000,000	80,000,000
Deferred Tax Liability	17.00	143,768,150	158,005,471
<b>Total Non-Current Liabilities</b>		<b>463,655,083</b>	<b>447,824,832</b>
<b>Current Liabilities:</b>			
Short Term Loan	18.00	4,743,439,850	5,008,191,502
Lease Liabilities (Current Maturity)	15.00	41,848,006	43,553,958
Long Term Loan (Current Maturity)	16.00	27,215,894	35,366,036
Trade and Other Payables	19.00	1,347,112,924	1,199,906,960
Unclaim Dividend Payable	20.00	7,309,457	7,764,971
<b>Total Current Liabilities</b>		<b>6,166,926,131</b>	<b>6,294,783,427</b>
<b>Total Liabilities</b>		<b>6,630,581,214</b>	<b>6,742,608,259</b>
<b>Total Equity and Liabilities</b>		<b>11,367,137,018</b>	<b>11,303,703,819</b>
Net Asset Value (NAV) Per Share	30.00	44.10	42.46

Annexed notes are integral part of these financial statements.

  
 Director Finance & CFO

  
 Company Secretary

  
 Acting Managing Director

  
 Director

  
 Chairman



**Navana Pharmaceuticals PLC.**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the period from 01 July 2024 to 31 December 2024**

(Amount in BDT)


Particulars	Notes	Half Yearly		Second Quarter	
		July-Dec'2024	July-Dec'2023	Oct-Dec'2024	Oct-Dec'2023
Net Sales	21.00	4,363,718,011	3,283,637,823	2,226,315,771	1,652,116,111
Less: Cost of Good Sold	22.00	2,336,947,999	1,753,983,777	1,201,093,153	878,668,658
<b>Gross Profit</b>		<b>2,026,770,012</b>	<b>1,529,654,046</b>	<b>1,025,222,618</b>	<b>773,447,453</b>
<b>Less: Operating Expenses</b>					
Administrative Expenses	23.00	104,071,396	84,529,284	59,328,344	51,550,092
Selling & Marketing Expenses	24.00	890,146,225	721,429,445	454,458,729	373,509,023
Distribution Expenses	25.00	289,078,585	237,839,980	155,297,467	121,603,136
<b>Total Operating Expenses:</b>		<b>1,283,296,206</b>	<b>1,043,798,709</b>	<b>669,084,540</b>	<b>546,662,251</b>
<b>Operating Profit</b>		<b>743,473,806</b>	<b>485,855,337</b>	<b>356,138,078</b>	<b>226,785,202</b>
Less: Finance Expenses	26.00	390,040,025	195,198,225	188,939,808	101,298,283
Add: Other Income/(loss)	27.00	1,454,575	13,192,764	15,057,436	10,053,512
<b>Profit Before WPPF &amp; Tax</b>		<b>354,888,356</b>	<b>303,849,875</b>	<b>182,255,706</b>	<b>135,540,431</b>
Contribution to WPPF		16,899,446	14,469,042	8,678,843	6,454,306
<b>Profit Before tax</b>		<b>337,988,911</b>	<b>289,380,833</b>	<b>173,576,863</b>	<b>129,086,125</b>
<b>Less: Income Tax</b>		<b>96,544,788</b>	<b>65,062,627</b>	<b>65,881,952</b>	<b>24,318,009</b>
Current Tax	28.00	84,303,261	57,540,543	64,534,799	21,948,248
Deferred Tax Expense/(Income)		12,241,527	7,522,084	1,347,152	2,369,760
<b>Profit After Tax</b>		<b>241,444,123</b>	<b>224,318,207</b>	<b>107,694,911</b>	<b>104,768,117</b>
<b>Other Comprehensive Income</b>					
Unrealized Gain/(loss) on Marketable Security		(141,676,173)	(17,140,400)	(130,968,518)	(9,315,188)
<b>Total Comprehensive Income</b>		<b>99,767,950</b>	<b>207,177,807</b>	<b>(23,273,607)</b>	<b>95,452,928</b>
<b>Earnings Per Share (EPS)</b>	29.00	<b>2.25</b>	<b>2.09</b>	<b>1.00</b>	<b>0.98</b>


Annexed notes are integral part of these financial statements.

  
 Director Finance & CFO

  
 Company Secretary

  
 Acting Managing Director

  
 Director

  
 Chairman



Navana Pharmaceuticals PLC

Statement of Changes in Equity (Un-audited)

For the period from 01 July 2024 to 31 December 2024

Particulars	Share Capital	Share Premium	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2024	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(123,143,306)	708,021,144	4,561,095,560
Profit after Tax	-	-	-	-	-	241,444,123	241,444,123
14% Cash Dividend for YE 30 June 2024	-	-	-	-	-	(47,451,013)	(47,451,013)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	(18,532,867)	-	(18,532,867)
<b>Balance as at 31 December 2024</b>	<b>1,074,162,170</b>	<b>448,170,069</b>	<b>1,848,295,335</b>	<b>605,590,148</b>	<b>(141,676,173)</b>	<b>902,014,254</b>	<b>4,736,555,803</b>


Statement of Changes in Equity (Un-audited)

For the period from 01 July 2023 to 31 December 2023


Particulars	Share Capital	Share Premium	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(46,800,998)	443,028,348	4,372,445,073
Profit after Tax	-	-	-	-	-	224,318,207	224,318,207
13% Cash Dividend for YE 30 June 2023	-	-	-	-	-	(139,641,082)	(139,641,082)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	(17,140,400)	-	(17,140,400)
<b>Balance as at 31 December 2023</b>	<b>1,074,162,170</b>	<b>448,170,069</b>	<b>1,848,295,335</b>	<b>605,590,148</b>	<b>(63,941,398)</b>	<b>527,705,473</b>	<b>4,439,981,797</b>

Annexed notes are integral part of these financial statements.

  
Director Finance & CFO

  
Company Secretary

  
Acting Managing Director

  
Director


  
Chairman





**Navana Pharmaceuticals PLC.**  
**Statement of Cash Flows (Un-audited)**  
**For the period from 01 July 2024 to 31 December 2024**


Particulars	Notes	July-Dec'2024	July-Dec'2023
<b>Cash Flows from Operating Activities:</b>		<b>339,265,300</b>	<b>93,133,612</b>
Cash Receipts from Customers		4,313,087,401	2,918,222,249
Cash Receipts from Other Income		(1,487,818)	11,964,064
Cash Paid to Suppliers		(2,150,918,695)	(1,604,567,549)
Bank & Lease Interest Paid		(359,176,452)	-
Cash paid to Employees and Others		(757,772,491)	(556,383,157)
Cash paid to Operational Expenses		(624,114,055)	(610,936,229)
Advance Income Tax Paid		(80,352,592)	(65,165,766)
<b>Cash Flows from Investing Activities:</b>		<b>(83,368,544)</b>	<b>(428,830,158)</b>
Property, Plant and Equipment		(109,674,028)	(441,374,221)
Realized Gain/(loss) from Sale of Marketable Securities		(10,457,145)	823,584
Cash received from Dividend Income		901,146	744,262
Cash Received/(Paid) from Investment in Marketable Securities		35,861,483	10,976,217
<b>Cash Flows from Financing Activities:</b>		<b>(244,995,688)</b>	<b>210,040,204</b>
Increase/ (Decrease) in Lease Liabilities		(11,680,289)	(27,114,885)
Increase/ (Decrease) in Long Term Loan		31,891,767	62,615,532
Increase/ (Decrease) in Short Term Loan		(264,751,652)	345,125,594
Bank & Lease Interest Paid		-	(170,556,546)
Unclaimed dividend Paid		(455,514)	(29,491)
<b>Increase/(Decrease) in cash &amp; cash equivalents</b>		<b>10,901,067</b>	<b>(125,656,341)</b>
Cash and Cash Equivalents at Beginning of year		267,770,086	440,930,216
Effect of exchange rate changes on Cash and Cash Equivalents		3,896,549	86,233
<b>Cash and Cash Equivalents at end of year</b>	11.00	<b>282,567,702</b>	<b>315,360,107</b>
<b>Net operating cash flows per share</b>	31.00	<b>3.16</b>	<b>0.87</b>

Annexed notes are integral part of these financial statements.

  
 Director Finance & CFO

  
 Company Secretary

  
 Acting Managing Director

  
 Director

  
 Chairman



**Navana Pharmaceuticals PLC.**  
**Notes to the Interim Financial Statements**  
**For the period 01 July 2024 to 31 December 2024**

**1.0 About the Company**

**1.01 Legal Form of the Company**

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

**1.02 Address of the Registered Office and Factory**

The address of the Company's registered office and Factory located at 1071,1073, North Rupshi, Tarabo, Municipality, Rugganj, Narayanganj. Corporate office address is House 99, Road 4, Block # B, Banani Dhaka-1213, Bangladesh. The Company has several depots around the country.

**1.03 Nature of Business Activities**

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

**2.00 Basis of Preparation and Presentation of Financial Statements**

**2.01 Preparation and Presentation of Financial Statements of the Company**

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals Ltd.

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2025 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

**2.02 Statement of Compliance**

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

**2.03 Regulatory Compliances**

As required by the Company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax ACT 2023
- b) Income Tax Rules 2023
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969 and Customs Act 2023
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

**2.04 Basis of Measurement**

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.



## 2.05 Reporting Period and Comparative Information

The Financial Statements cover 06 months period starting from July 01, 2024 to December 31, 2024

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement of Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IASs & IFRSs whenever it is relevant for the understanding of the current Period financial statements.

## 2.06 Rearrangement of Financial Statement:

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

## 2.07 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

## 2.08 Property, Plant and Equipment (PPE)

### Recognition and Measurement:

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.

### Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

### Subsequent Costs

The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenances costs are charged to the Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they incurred.

### Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

### Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Depreciation on Property, Plant and Equipment has been compute during the periods using reducing balance method except Land & Land Development. Depreciation has been charged on addition when the related PPE are available.

After considering the useful life of assets as per IAS 16, the annual depreciation rates have been applied as under which is considered reasonable by the management.

### Rate of Depreciation:

Particulars	Rate	Particulars	Rate
<b>Land and Land Development</b>		<b>Vehicles</b>	
Land and Land Development	Nil	Transport & Vehicles	20%
<b>Building &amp; Other Construction</b>		Motor Cycle	20%
Factory Building	10%	<b>Furniture &amp; Fixture</b>	
Office Decoration	10%	Furniture & Fixtures	10%
Pump House Construction	20%	Rack & Pallets	15%



Particulars	Rate	Particulars	Rate
Store Room	15%	<b>Office Equipment's</b>	
Office Room Extension	10%	Fire Extinguishers	15%
Factory Decoration	10%	Office Equipment's	15%
Factory Wall	10%	Air Cooler	20%
Pre Fabrication Building	10%	Cookeries & Cutleries	10%
Solvent Store	15%	Telephone Line Installation	15%
<b>Plant &amp; Machinery</b>		Photocopier & Fax Machine	20%
Plant & Machinery	20%	Projector	15%
Electrical Installation	20%	Refrigerator	20%
Generator	20%	Mobile	20%
Gas Line Installation	20%	<b>Computer &amp; IT Accessories</b>	
Spare Parts	20%	Computer	25%
ETP	20%	IT Accessories	25%
Electric Sub Station	20%	<b>Other Assets</b>	
<b>Lab Equipment</b>		Sundry Assets	15%
Quality Control Equipment	15%	Books	10%
Tools & Equipment's	15%	Software	20%

**2.09 Intangible Assets**

Software are amortized over 5 periods based on straight line method from the date when assets are available for use. The amount of amortization has been presented under the statement of rate of amortization on software is as under.

**2.10 Events after the Reporting Period**

Events after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

**2.11 Company Name Change to Navana Pharmaceuticals PLC**

In accordance with the Amendment of The Companies Act 1994 (Amendment up to 2020), the company has decided to change its name from Navana Pharmaceuticals Ltd. to Navana Pharmaceuticals PLC. All necessary regulatory approvals have already been obtained.



Notes	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>3.00</b>	<b>Property Plant and Equipment: Tk. 4,997,974,408</b>		
	This is made up as follows: (details shown in Annex A)		
	<b>Cost</b>		
	Opening Balance	3,647,483,437	2,650,971,843
	Addition during the period	464,284,352	1,012,118,013
	Adjustment/disposal during the period	(312,784)	(15,606,419)
	<b>Closing Balance</b>	<b>4,111,455,005</b>	<b>3,647,483,437</b>
	<b>Revaluation</b>		
	Opening Balance	1,966,271,632	1,966,271,632
	Adjustment due to revaluation during the period	-	-
	<b>Closing Balance</b>	<b>1,966,271,632</b>	<b>1,966,271,632</b>
	<b>Total Cost &amp; Revaluation</b>	<b>6,077,726,637</b>	<b>5,613,755,069</b>
	<b>Depreciation</b>		
	Opening Balance	962,813,732	806,861,796
	Charged during the period	117,134,258	171,251,750
	Adjustment during the period	(195,761)	(15,299,814)
	<b>Closing Balance</b>	<b>1,079,752,229</b>	<b>962,813,732</b>
	<b>Written Down Value</b>	<b>4,997,974,408</b>	<b>4,650,941,337</b>
<b>3.01</b>	<b>Intangible Assets: Tk. 220,000</b>		
	This is made up as follows:		
	<b>Cost</b>		
	Opening Balance	1,100,000	1,100,000
	Addition during the period	-	-
	<b>Total Cost</b>	<b>1,100,000</b>	<b>1,100,000</b>
	<b>Depreciation</b>		
	Opening Balance	770,000	550,000
	Charged during the period	110,000	220,000
	<b>Closing Balance</b>	<b>880,000</b>	<b>770,000</b>
	<b>Written Down Value</b>	<b>220,000</b>	<b>330,000</b>
<b>4.00</b>	<b>Capital Work In Progress: Tk. 546,570,161</b>		
	This is made up as follows:		
	Opening Balance	931,717,844	614,665,799
	Add: Addition during the period:		
	Construction of New Generic Production Unit	53,500,000	-
	Modernization and expansion of General Liquid Facility with dispensing area	766,299	37,977,309
	Modernization and expansion of Animal Health Facility	-	10,448,737
	Construction of new Utility and Engineering Building	270,000	31,773,650
	Refurbishment of cephalosporin unit	-	73,159,298
	BMRE and Machinery	4,440,998	939,095,421
		<b>990,695,141</b>	<b>1,707,120,214</b>
	<b>Less: Capitalized during the period</b>		
	Transfer to PPE	(444,124,980)	(775,402,370)
	<b>Closing Balance</b>	<b>546,570,161</b>	<b>931,717,844</b>
<b>5.00</b>	<b>Right-of-Use Asset: Tk. 145,774,909</b>		
	Written Down Value	<b>145,774,909</b>	<b>163,404,672</b>
<b>6.00</b>	<b>Investment in Marketable Securities (Fair Value): Tk. 41,058,755</b>		
	This is made-up as follows:		
	Opening total cost of marketable securities	200,063,544	214,420,832
	Cost value of sales of share	(17,328,616)	(14,357,288)
	<b>Closing balance cost Value</b>	<b>182,734,928</b>	<b>200,063,544</b>
	Unrealized gain/(loss)	(141,676,173)	(123,143,306)
	<b>Closing market value securities</b>	<b>41,058,755</b>	<b>76,920,238</b>
	During the period total Realized Gain/(loss) from sale of marketable securities is (Tk.) (10,457,154)		



Notes	Particulars	Amount in BDT	Amount in BDT
		31-Dec-24	30-Jun-24
<b>7.00</b>	<b>Inventories: Tk. 1,525,390,572</b>		
	This is made-up as follows:		
	Raw Material	606,688,224	473,451,176
	Packing Material	128,719,692	141,963,452
	Finished Goods	653,393,867	565,590,306
	Work-in-Process	84,786,654	77,078,776
	Printed & Gifted Promotional Stock	51,802,135	25,105,000
	<b>Total</b>	<b>1,525,390,572</b>	<b>1,283,188,710</b>
<b>8.00</b>	<b>Trade and Other Receivables: Tk. 1,080,806,310</b>		
	This is made-up as follows:		
	Trade Receivables-Local Sales	909,790,247	915,824,397
	Trade Receivables-Export Sales	134,876,154	80,738,506
	Receivable Export Cash Incentive	34,777,900	23,106,132
	Dividend Receivable	901,147	-
	Interest Receivable on FDR	460,862	460,862
	<b>Total</b>	<b>1,080,806,310</b>	<b>1,020,129,897</b>
	Export Receivable as at 31 December 2024 total \$ 1,105,542 has been translated @ Tk. 1220 average spot rate and resulting unrealized gain of Tk. 3,896,549 has been reported under 'FOREX Gain/(Loss) Account'.		
<b>9.00</b>	<b>Advances, Deposits and Prepayments: Tk. 2,031,924,349</b>		
	This is made-up as follows:		
	Advance for suppliers (others)	40,227,720	86,570,654
	Advance for raw/packing purchase	156,999,069	261,120,477
	LC margin for raw material	84,068,392	117,828,568
	VAT paid on finished goods	149,563,297	131,166,700
	Security money	2,920,519	6,344,210
	Advance to depot	70,517,272	44,189,884
	Advance against salary & allowanc	12,248,522	11,977,354
	Advance against lease for vehicles	847,524	847,524
	Advance against customs duty	14,496,798	23,662,933
	Advance income tax	600,768,781	520,416,189
	Advance for capital expense	866,413,206	920,949,505
	LC Margin for capital goods	32,853,250	26,020,000
	<b>Total</b>	<b>2,031,924,349</b>	<b>2,151,093,999</b>
<b>10.00</b>	<b>Goods In Transit: Tk. 714,849,852</b>	<b>714,849,852</b>	<b>758,207,036</b>
<b>11.00</b>	<b>Cash and Cash Equivalents: Tk. 282,567,702</b>		
	This is made-up as follows:		
	<b>Cash at Bank</b>		
	Jamuna Bank Ltd., Rupshi Br. A/c. 1661	-	211,619
	Pubali Bank Ltd., Dhaka Stadium Br. A/c 473	6,334,097	12,933,628
	Southeast Bank Ltd., Corporate Br. CD A/C No.648	450,872	1,106,015
	Southeast Bank Ltd., Corporate Br. CD A/C No 7614	234,755	328,852
	Dutch Bangla Bank Ltd., Local Office, CD A/C No.957	10,259,466	4,375,173
	Sonali Bank Ltd., Customs House Br. A/c 379	6,358,024	5,061,575
	Al Arafah Islami Bank Ltd., VIP Road Br. ERQ A./c-46	76,570	1,580,147
	Al Arafah Islami Bank Ltd., VIP Road Br.DAD A./c-44	967,177	2,543,943
	United Commercial Bank Ltd., Gulshan Br., A./c-0011	12,656,952	21,411,461
	United Commercial Bank Ltd., Gulshan Br. A./c-0055	3,657	4,207
	United Commercial Bank Ltd., SND A.C-162	-	3,075
	Dhaka Bank Ltd. Banani Br. A/c-28321	-	(237)
	NRBC Bank Ltd., Gulshan Br. -SND 033	99,200	99,200
	Shimanto Bank Ltd.Corp. Br., CD-012	724,188	2,895,595
	Community Bank BD Ltd.-9101	-	307,829
	Bengal Commercial Bank, Corp Br.-1467	781,291	292,139
	Pubali Bank Ltd. Faridpur Br. A./c-160	523,800	1,115,563
	Pubali Bank Ltd., Mymensingh Br.- A/c 294	596,916	500,790
	Pubali Bank Ltd., Dargagate Br. A./c-125	1,156	285,130
	Pubali Bank Ltd., Kamalpur Br., A/c-25303	1,979	623
	Pubali Bank Ltd., Maizdee Court Br. A./c-840	205,180	823,985
	Pubali Bank Ltd., Momin Road Br. A./c-8940	1,519	2,624
	Southeast Bank Ltd., Barisal Br. A./c-051	2,630	3,915



Notes	Particulars	Amount in BDT	Amount in BDT
		31-Dec-24	30-Jun-24
	Southeast Bank Ltd., Bogra Br. A./c-246	353	923
	Southeast Bank Ltd., Comilla Br. A./c-044	358	928
	Southeast Bank Ltd., Corporate Br.A./c-8200	2,811	3,270
	Southeast Bank Ltd., Cox's Bazar Br. A./c-091	435	54,900
	Southeast Bank Ltd., Dinajpur Br.-A/c 0144	725	2,020
	Southeast Bank Ltd., Jessore(SME) Br. A./c-347	476	936
	Southeast Bank Ltd., Joydevpur Br., A./c-027	7,259	10,891
	Southeast Bank Ltd., Khulna Br. A./c-925	385	845
	Southeast Bank Ltd., Rajshahi Br. A./c-014	1,159	1,954
	Southeast Bank Ltd., Rangpur Br. A./c-284	3,266	4,547
	One Bank, Principal Br. A/c 9942	1,665	1,665
	United Commercial Bank, Tangail A/c-4138	7,019	299,938
	United Commercial Bank, Pabna A/c-8094	196,993	1,028
	United Commercial Bank, N'Ganj Ac-10079	878	899,913
	United Commercial Bank, Feni-0138	201,527	604,988
	United Commercial Bank, Br Ac-304	699,758	4,368
	United Commercial Bank, Br Ac-462	448	4,368
	United Commercial Bank, Br Ac-362	115,908	709,368
	United Commercial Bank, Br Ac-328	297,333	479,368
	United Commercial Bank, Br Ac-168	5,333	149,368
	United Commercial Bank, Br Ac-268	7,448	571,368
	United Commercial Bank, Br Ac-164	7,448	1,368
	United Commercial Bank, Br Ac-183	499,873	34,368
	United Commercial Bank, Br Ac-334	500,447	184,368
	United Commercial Bank, Br Ac-188	100,332	4,368
	United Commercial Bank, Br Ac-358	10,448	814,368
	United Commercial Bank, Br Ac-034	201,723	519,643
	United Commercial Bank, Br Ac-247	56,908	1,150,368
	Commercial Bank of Ceylon PLC 7841	9,655	9,655
	AIBL SND , Ac # 0141220032027	23,170	10,381
	Meghna Bank Plc # 110113500000181	2,210,660	4,195
	United Commercial Bank, Bond A/c-2258	3,620	4,166
	Prime Bank , Banani Br. A./C CD-26074	21,540	-
	Standard Chartered Bank Ltd.Gulshan Br. Ac CD-28001	4,582,016	306,071
		<b>53,710,136</b>	<b>69,203,956</b>
	FDR	63,000,000	33,000,000
	United Commercial Bank Ltd., IPO A/C-3209	101,548,963	120,119,623
	AIBL-13%CashDivid-141220031994	5,470,439	5,448,991
	United Commercial Bank Ltd. Ac-1971 (11% Cash Dividend, 2023)	2,349,175	2,338,190
	NPL 14% cash Dividend 2023-2024	4,195	-
	Cash in Hand	56,484,794	37,659,326
	<b>Total</b>	<b>282,567,702</b>	<b>267,770,086</b>
	a. The reconciliation of bank balance has been performed and found in order.		
	b. Cash in hand has been counted by the management at the period end.		
<b>12.00</b>	<b>Paid-up Share Capital: Tk. 1,074,162,170</b>		
	This is made-up as follows:		
	<b>A. Authorised Capital:</b>		
	200,000,000 Ordinary Shares of Tk. 10 each	2,000,000,000	2,000,000,000
	<b>B. Issued Subscribed &amp; Paid up Capital:</b>		
	107,416,217 Ordinary Shares of Tk. 10 each	1,074,162,170	1,074,162,170
	<b>Closing Balance</b>	<b>1,074,162,170</b>	<b>1,074,162,170</b>
<b>13.00</b>	<b>Revaluation Reserve: Tk. 1,848,295,335</b>		
	This is made-up as follows:		
	Opening Balance	1,848,295,335	1,966,271,633
	Less: Adjusted during the period		(117,976,298)
	<b>Revaluation Reserve:</b>	<b>1,848,295,335</b>	<b>1,848,295,335</b>
<b>14.00</b>	<b>Loan from Directors: Tk. 30,000,000</b>		
	This is made-up as follows:		
	Opening Balance	30,000,000	30,000,000
	<b>Closing Balance</b>	<b>30,000,000</b>	<b>30,000,000</b>



Notes	Particulars	Amount in BDT	Amount in BDT
		31-Dec-24	30-Jun-24
<b>15.00</b>	<b>Lease Liabilities: Tk. 96,373,764</b>		
	This is made-up as follows:		
	<b>Opening balance</b>	108,054,053	124,315,723
	Add: Addition during the year for ROUA for Vehicle	(11,680,289)	(16,261,670)
	Less: Payment during the year		
	<b>Closing balance</b>	<u>96,373,764</u>	<u>108,054,053</u>
<b>15.00</b>	Principal Payment due within one year	41,848,006	43,553,958
<b>15.01</b>	Principal Payment due more than one year	54,525,758	64,500,095
	<b>Total</b>	<u>96,373,764</u>	<u>108,054,053</u>
<b>16.00</b>	<b>Long Term Loan: Tk. 182,577,069</b>		
	This is made-up as follows:		
<b>16.00</b>	Payment due within one period	27,215,894	35,366,036
<b>16.01</b>	Principal Payment due more than one year	155,361,175	115,319,266
	<b>Total</b>	<u>182,577,069</u>	<u>150,685,302</u>
<b>17.00</b>	<b>Deferred Tax Liability: Tk. 143,768,150</b>		
	This is made-up as follows:		
	Opening Balance	146,501,877	169,640,474
	Addition during the year:		
	Deferred Tax on Broken and Damage	(1,743,978)	645,035
	Deferred Tax on PPE and ROUA	13,823,524	-
	Deferred Tax on Lease Liability	(24,312,162)	(23,783,631)
	<b>Total</b>	<u>134,269,260</u>	<u>146,501,877</u>
	Less: Deferred Tax Asset	(9,498,890)	(11,503,594)
	<b>Net Deferred Tax Liability Balance</b>	<u>143,768,150</u>	<u>158,005,471</u>
<b>18.00</b>	<b>Short Term Loan: Tk. 4,743,439,850</b>		
	This is made-up as follows:		
	Bank Overdraft	1,877,500,000	1,886,549,502
	LTR, UPAS Loan	1,700,649,016	1,673,542,529
	Time Loan	1,050,406,401	1,334,659,639
	Margin Loan for Investment in Securities	114,884,433	113,439,831
	<b>Total</b>	<u>4,743,439,850</u>	<u>5,008,191,502</u>
<b>19.00</b>	<b>Trade and Other Payables: Tk. 1,347,112,924</b>		
	This is made-up as follows:		
	Trade & other Payables	21,495,732	23,791,543
	Payable Salary and Daily Field	104,471,528	110,666,864
	VAT Payable (Treasure)	56,504,715	53,676,568
	Payable Audit Fee	211,250	402,500
	Payable for Other Supplies	724,352	824,352
	Payable Director Remuneration	547,416	584,290
	Payable-Sales Center Rent	1,700,365	1,421,075
	Payable for Utility	3,175,372	701,891
	Provision for Gratuity	77,935,272	70,184,257
	Provision for Bad Debt	14,680,203	13,064,358
	Provision for Broken, Damage & Expiry	343,735	312,486
	Provision for Income Tax	535,503,825	451,200,564
	Provision for W.P.P.F	42,039,366	25,139,919
	Interest Payable on Short Term Loan	198,058,883	167,225,310
	Interest Payable on Term Loan	979,389	949,389
	Interest Payable on Bond	5,796,000	-
	Withholding Tax Payable	4,049,848	4,049,848
	Payable for Earned Leave Encashment	20,051,780	13,367,853
	Payable for TDS and VDS for Capex	258,843,894	262,343,894
	<b>Total</b>	<u>1,347,112,924</u>	<u>1,199,906,960</u>
<b>20.00</b>	<b>Unclaim Dividend payable: Tk. 7,309,457</b>		
	Year Wise Break-up:		
	2021-2022	2,024,967	2,336,928
	2022-2023	5,284,490	5,428,043
	<b>Total</b>	<u>7,309,457</u>	<u>7,764,971</u>



Notes	Particulars	Amount in BDT	Amount in BDT
		01 Jul-31 Dec 24	01 Jul-31 Dec 23
<b>21.00</b>	<b>Sales: Tk. 4,363,718,011</b>		
	This is made-up as follows:		
	Local Sales Human Health	4,142,283,900	2,987,137,205
	Export Sales	220,762,872	114,400,716
	Local Sales Animal Health	680,000,513	733,547,159
	<b>Gross sales</b>	<b>5,043,047,285</b>	<b>3,835,085,080</b>
	Less: Value Added Tax (VAT)	679,329,274	551,447,257
	<b>Net sales</b>	<b>4,363,718,011</b>	<b>3,283,637,823</b>
	<b>Breakup of Net Turnover</b>		
	Local Sales Human Health Division	3,500,435,355	2,544,409,885
	Export Sales	220,762,872	114,400,716
	Local Sales Animal health division	642,519,784	624,827,222
	<b>Total</b>	<b>4,363,718,011</b>	<b>3,283,637,823</b>
	a. Sales figure is presented on net of VAT in the statement of profit or loss and other comprehensive income.		
	b. Sales has increased due to strong branding, marketing and improved economic condition.		
<b>22.00</b>	<b>Cost of Sales: Tk. 2,336,947,998</b>		
	This is made-up as follows:		
	Raw Material Consumption (Note No: 22.01)	1,465,960,933	1,239,762,467
	Packing Material Consumption (Note No: 22.02)	788,480,712	632,834,470
	Factory Expenses (Note No: 22.03)	260,829,312	230,287,221
	<b>Total Manufacturing Cost</b>	<b>2,515,270,956</b>	<b>2,102,884,157</b>
	Opening Stock Work-In-Process	54,164,496	96,348,470
	Closing Stock Work-In-Process	(84,786,654)	(54,164,496)
	<b>Cost of Production</b>	<b>2,484,648,798</b>	<b>2,145,068,131</b>
	Opening Stock Finished Goods	565,590,306	508,936,313
	<b>Finished goods available for sale</b>	<b>3,050,239,104</b>	<b>2,654,004,444</b>
	Cost of Physician Sample transferred to Marketing Exp.	(27,843,281)	(17,418,189)
	Cost of Bonus Product transferred to Marketing Exp.	(32,053,958)	(24,255,215)
	Closing Stock Finished Goods	(653,393,867)	(858,347,263)
	<b>Cost of Goods Sold</b>	<b>2,336,947,998</b>	<b>1,753,983,777</b>
<b>22.01</b>	<b>Raw Material Consumption: Tk. 1,465,960,933</b>		
	This is made-up as follows:		
	Opening Stock of Raw Materials	473,451,176	378,760,941
	Add: Purchase during the period	1,599,197,981	1,158,839,117
	Less: Closing Stock of Raw Materials	(606,688,224)	(297,837,591)
	<b>Closing Balance</b>	<b>1,465,960,933</b>	<b>1,239,762,467</b>
<b>22.02</b>	<b>Packing Material Consumption: Tk. 788,480,712</b>		
	This is made-up as follows:		
	Opening Stock of Packing Materials	141,963,452	113,570,761
	Add: Purchase during the period	775,236,952	557,312,109
	Less: Closing Stock of Packing Materials	(128,719,692)	(38,048,400)
	<b>Closing Balance</b>	<b>788,480,712</b>	<b>632,834,470</b>
<b>22.03</b>	<b>Factory Expenses: Tk. 260,829,312</b>		
	This is made-up as follows:		
	Salary & Allowance	83,161,613	64,817,995
	Festival Bonus	6,312,504	8,402,397
	Contribution to Provident Fund	4,635,357	3,219,746
	Holiday Allowance & Overtime	9,128,086	9,514,483
	Cylinder Expenses	-	372,000
	Diesel for generator	6,439,770	2,891,113
	Electricity Bill	16,965,471	20,335,467
	Entertainment	1,533,363	1,510,001
	Renewal Fees	255,323	125,235
	Fees & Forms	15,733	207,840
	Insurance Premium-Fire & Burglary	3,240,379	1,178,511
	Gas Bill	1,483,043	1,004,783
	Group Insurance Premium	-	59,510
	Laboratory Chemicals	10,623,512	9,088,299
	Medical Expenses	17,870	28,272
	Newspaper & Periodicals	12,438	1,964
	Repair & Maintenance	2,594,412	2,941,866
	Medical Waste Management Expense	2,236,032	1,386,510
	Sanitation Expense	2,562,884	1,208,301



Notes	Particulars	Amount in BDT	
		01 Jul-31 Dec 24	01 Jul-31 Dec 23
	Spare Parts for machinery	5,146,276	11,294,887
	Depreciation on PPE & ROUA	80,938,335	66,384,712
	Other Business Expenses	20,836,498	24,313,328
	<b>Total</b>	<b>260,829,312</b>	<b>230,287,221</b>
<b>23.00</b>	<b>Administrative Expenses: Tk. 104,071,396</b>		
	This is made-up as follows:		
	Salary and Allowances	38,431,054	23,089,337
	Festival Bonus	4,673,191	2,861,483
	Contribution to Provident Fund	2,221,424	3,019,266
	Gratuity	3,948,302	3,000,000
	Audit Fees	211,250	175,000
	Board Meeting Fee	396,000	401,500
	Audit Committee & NRC Meeting Fee	192,500	154,000
	Professional Fees	1,832,941	894,665
	Advertising Expenses	730,976	907,494
	Director's Remuneration	3,900,000	4,878,000
	Electricity Bill	1,629,985	1,998,545
	Registration Fees and Renewal Fees	146,015	454,348
	Foreign Tour Expenses	2,524,800	2,142,108
	Depreciation on Rental Asset (Annex-ROUA)	7,053,204	3,976,256
	Depreciation Other than Rental Asset (Annex-PPE)	11,219,801	8,852,868
	Amortization on software	110,000	110,000
	Other Business Expenses	13,576,250	27,614,414
	<b>Total</b>	<b>104,071,396</b>	<b>84,529,284</b>
	As per IFRS 16-Leases Office Rent for current period has been presented under Depreciation.		
<b>24.00</b>	<b>Selling &amp; Marketing Expenses: Tk. 890,146,225</b>		
	This is made-up as follows:		
	Salary and Allowances	453,160,612	336,515,822
	Festival Bonus	39,936,746	33,515,019
	Contribution to Provident Fund	22,036,046	17,427,912
	Incentives	31,397,374	17,095,784
	Gratuity	4,474,266	2,250,000
	Stationery	1,291,480	2,355,453
	Daily Expenses for Field workers	159,933,462	161,936,043
	Travelling and Conveyance	7,095,526	1,108,756
	Bonus On Sales	32,053,958	24,255,215
	Printed & Gifted Promotional Expenses	28,466,788	27,568,144
	Sample Expenses	27,843,281	17,418,189
	Depreciation on PPE & ROUA	6,087,740	6,484,236
	Product Expiry Replacement	22,253,436	18,177,949
	Brand Development & New Product	10,404	4,436,648
	Other Business Expenses	48,634,086	50,884,274
	<b>Total</b>	<b>890,146,225</b>	<b>721,429,445</b>
<b>25.00</b>	<b>Distribution Expenses: Tk. 289,078,585</b>		
	This is made-up as follows:		
	Salary and Allowances	98,755,488	72,914,924
	Festival Bonus	8,258,690	6,651,191
	Contribution to Provident Fund	4,505,867	2,022,805
	Repair & Maintenance	2,997,982	1,745,848
	Stationery	3,690,784	2,887,723
	Daily Expenses for Field workers	50,506,906	35,806,520
	Holiday Allowance & Overtime	2,891,447	2,471,971
	Insurance Premium Fire & Burglary	498,000	254,179
	Group Insurance Premium	-	99,510
	Depreciation on PPE & ROUA	34,086,673	39,930,658
	Other Business Expenses	82,886,748	73,054,651
	<b>Total</b>	<b>289,078,585</b>	<b>237,839,980</b>
<b>26.00</b>	<b>Finance Expenses: Tk. 390,040,025</b>		
	This is made-up as follows:		
	Interest charged on Short term loan	365,793,866	162,762,088
	Interest on Other loan/(Bond)	2,867,781	-
	Bank Charges	3,043,821	4,704,296
	Bank Charges-Export	710,949	3,343,631
	BO Charges, Interest on margin Loan	6,999,067	8,524,767
	Interest on Term Loan	4,884,290	8,130,489
	Interest on Lease Finance	5,740,251	7,732,955
	<b>Total</b>	<b>390,040,025</b>	<b>195,198,225</b>



Notes	Particulars	Amount in BDT	
		01 Jul-31 Dec 24	01 Jul-31 Dec 23
<b>27.00</b>	<b>Other Income/ (Loss): Tk. 1,454,575</b>		
	This is made-up as follows:		
	Cash Incentive	11,964,386	10,007,382
	Bank Interest	305,240	119,280
	Interest on FDR	465,825	495,000
	Dividend Income	901,146	744,262
	Sale of Wastage	2,305,190	2,754,668
	FOREX Gain/(loss)	(5,166,003)	(8,441,546)
	Gain on disposal of FA	(74,523)	1,460,000
	Realized Gain/(loss) from Sale of Marketable Securities	(10,457,145)	823,584
	Income from PF Contribution Forfeiture	1,210,459	5,230,133
	<b>Total</b>	<b>1,454,575</b>	<b>13,192,764</b>
<b>28.00</b>	<b>Income Tax: Tk. 96,544,788</b>		
	This is made-up as follows:		
	Current period Tax	84,303,261	57,540,543
	Deferred Tax Expense/ (Income)	12,241,527	7,522,084
	<b>Total</b>	<b>96,544,788</b>	<b>65,062,627</b>
<b>29.00</b>	<b>Earnings Per Share (EPS)</b>		
	Earnings attributable to the Ordinary Shareholders	241,444,123	224,318,207
	Weighted Avg. Number of Ordinary Shares	107,416,217	107,416,217
	<b>Earnings Per Share (EPS)</b>	<b>2.25</b>	<b>2.09</b>
<b>30.00</b>	<b>Net Asset Value (NAV) Per Share</b>		
	Total Assets	11,367,137,018	11,303,703,819
	Less: Total Liabilities	6,630,581,214	6,742,608,259
	<b>Net Assets</b>	<b>4,736,555,804</b>	<b>4,561,095,560</b>
	Number of Ordinary Shares	107,416,217	107,416,217
	<b>Net Asset Value (NAV) Per Share</b>	<b>44.10</b>	<b>42.46</b>
<b>31.00</b>	<b>Net Operating Cash Flow Per Share (NOCFPS)</b>		
	Net Cash Generated from Operating Activities	339,265,300	93,133,612
	Number of Ordinary Shares	107,416,217	107,416,217
	<b>Net Operating Cash Flow Per Share (NOCFPS)</b>	<b>3.16</b>	<b>0.87</b>
<b>32.00</b>	<b>Reconciliation of Cash Flows from Operating Activities</b>		
	A reconciliation of net income or net profit with cash flow from operating activities:		
	<b>Net Profit Before Tax for the period</b>	<b>337,988,911</b>	<b>289,380,833</b>
	<b>Adjustment to reconcile net income to net cash provided by operating activities:</b>		
	Depreciation and Amortization	134,874,022	125,738,730
	Realized Gain/(loss) on Marketable Securities	(10,457,145)	823,584
	Unrealized Foreign Exchange Gain/(Loss)	(5,166,003)	1,515,909
	Gain on Disposal of FA	-	1,460,000
	Bank & Lease Interest		178,625,532
	WPPF Provision	16,899,446	14,469,042
	Income Tax Paid	(80,352,592)	(65,165,766)
	<b>Increase/Decrease in Current Assets:</b>		
	Inventory Decrease/(Increase)	(242,201,862)	(152,550,295)
	Goods in transit Decrease/(Increase)	43,357,184	(60,205,581)
	Accounts Receivable Decrease/(Increase)	(60,676,413)	(370,261,717)
	Advance Deposit & Prepayment Decrease/(Increase)	119,169,650	40,618,093
	<b>Increase/Decrease in current Liabilities:</b>		
	Trade and Other Payables Increase/(Decrease)	85,830,102	88,685,248
	<b>Net Cash Generated by Operating Activities</b>	<b>339,265,300</b>	<b>93,133,612</b>
<b>33.00</b>	<b>Events After the Reporting Period</b>		
	There are no significant events after the reporting period to present.		



Notes	Particulars	Amount in BDT	
		01 Jul-31 Dec 24	01 Jul-31 Dec 23

**34.00 Related Party Disclosure**

The name of the related parties nature of transaction and their respective period end balance have been set out in accordance with the provisions of Para 18 Disclosure of Transaction between Related Parties of IAS 24 'Related Party Disclosure's. The company in normal course of business carried out transactions at fair value with following related parties:

Name of the Related Party	Relationship	Nature of Transaction	Balance as at 1 July 2024	Transaction July'24-Dec'24	Balance as at 31 Dec 2024
Professor Dr. Jonaid Shafiq	Managing Director	Director Remuneration	308,320	2,070,868	293,758
Dr. Sayeed Ahmed	Deputy Managing Director	Director Remuneration	275,970	1,797,918	253,658

As per Para-17, IAS 24: An entity shall disclose key management personnel compensation in total and for each of the following benefits:

Short Term Employee Benefit	Designation	Particulars	Transaction during the period	Outstanding as on 31-12-2024
<b>Name</b>				
Professor Dr. Jonaid Shafiq	Managing Director	Director Remuneration	2,100,000	350,000
Dr. Sayeed Ahmed	Deputy Managing Director	Director Remuneration	1,800,000	300,000

**Board Meeting Fee:** Board Meeting Fee: There were 9 Nos. Board of Directors meeting was held during the first quarter (Q2) of financial year-2024-2025 for the period July 01, 2024 to December 31, 2024, BDT 396,000 was paid as Board meeting fee to the Board members who attended the meeting for their attendance

**Audit Committee Meeting Fee:** There were 4 Nos. AC meeting was held during the first quarter (Q2) of financial year-2024-2025 for the period July 01, 2024 to December 31, 2024, BDT 110,000 was paid as AC meeting fee to the members of the AC who attended the meeting for their attendance.

**Nomination and Remuneration Committee Fee:** There were 3 Nos. NRC meeting was held during the first quarter (Q2) of financial year-2024-2025 for the period July 01, 2024 to December 31, 2024, BDT 82,500 was paid as NRC meeting fee to the members of the NRC who attended the meeting for their attendance.

(b) Not paid any Post-employee benefits

(c) Not paid any Other long term benefits

(d) Not paid any Termination benefits

(e) Not paid any Share-based payment

**35.00 Contingent Assets**

There was no contingent assets as at 31 December 2024.

**36.00 Contingent Liability**

110,976,846

110,976,846

**37.00 Litigation Pending**

1. For Non-payment of VAT which the legal experts estimated cost is Tk. 40,000,000/-. It has been stayed by High Court till 04-11-2024.
2. VAT demand of Tk. 31,982,604.12/- for Animal Health Product- "Pusti Premix". It was stayed by High Court on 14-01-2016 until final verdict of court.
3. Demand for Non-payment of VAT & interest to the extent to Tk. 8,666,739.22 by Customs Excise & VAT Commissionerate Dhaka (East) against Navana Health Care past audit reports. It has been stayed by High Court till 09-09-2025.
4. A petition is filed with High Court against unreasonable demand of Tk. 30,327,503 by Income Tax Tribunal u/s 83(2)/156/159 for AY 2015-16 (11 month).
5. A petition has been filed with Jugma Zilla Judge Court of Narayanganj for reclaiming 30 decimal land opposite of Factory at Rupshi Rupgonj. It is expected to be favorable.

**38.00 Bank Guarantee on behalf of the company provided by following Banks:**


1. Al-Arafah Islami Bank Limited VIP Road Branch-Tk. 9,945,908/-
2. Community Bank Bangladesh PLC, Corporate Branch Tk. 4,167,000
3. Standard Chartered Bank, Gulshan Branch-Tk. 7,166,866/-

  
Director Finance & CFO

  
Company Secretary

  
Acting Managing Director

  
Director

  
Chairman



**Navana Pharmaceuticals PLC.**  
Schedule of Property, Plant and Equipment  
As at 31 December 2024

Sl. No.	Particulars	Balance as on 01 July 2024			COST			Balance as on 31 Dec 2024			DEPRECIATION			Balance as on 31 Dec 2024		Written Down Value 30 June 2024
		Cost	Revaluation Reserve	Total	Cost	Revaluation Reserve	Total	Adjustment	Cost	Revaluation Reserve	Total	Charged during the year	Adjustment	Value 31 Dec 2024	Written Down Value 30 June 2024	
<b>1</b>	<b>Land and Land Development</b>	516,631,355	1,966,271,633	2,482,902,988	516,631,355	1,966,271,633	2,482,902,988	-	1,966,271,633	2,482,902,988	-	-	2,482,902,988	2,482,902,988	2,482,902,988	
	Land and Land Development	516,631,355	1,966,271,633	2,482,902,988	516,631,355	1,966,271,633	2,482,902,988	-	1,966,271,633	2,482,902,988	-	-	2,482,902,988	2,482,902,988	2,482,902,988	
<b>2</b>	<b>Building &amp; Other Construction</b>	1,414,819,374	184,718,200	1,599,537,574	1,517,496,348	1,517,496,348	1,517,496,348	184,718,200	1,517,496,348	1,517,496,348	184,718,200	53,860,430	399,402,250	1,200,135,324	1,069,206,556	
	Factory Building	1,332,738,148	184,718,200	1,517,456,348	1,517,496,348	1,517,496,348	1,517,496,348	184,718,200	1,517,496,348	1,517,496,348	184,718,200	51,653,515	359,458,662	1,158,042,833	1,024,973,062	
	Office Decoration	17,328,480	-	17,328,480	17,328,480	-	17,328,480	-	17,328,480	17,328,480	-	363,396	-	6,904,517	2,267,913	
	Pump House Construction	3,970	-	3,970	3,970	-	3,970	-	3,970	3,970	-	-	-	-	-	
	Store Room	27,480	-	27,480	27,480	-	27,480	-	27,480	27,480	-	18	-	236	236	
	Office Room Extension	829,201	-	829,201	829,201	-	829,201	-	829,201	829,201	-	5,062	-	96,186	101,248	
	Factory Decoration (BMBE)	48,150,595	-	48,150,595	48,150,595	-	48,150,595	-	48,150,595	48,150,595	-	223,162	-	32,032,533	31,718,406	
	Factory Wall	3,177,143	-	3,177,143	3,177,143	-	3,177,143	-	3,177,143	3,177,143	-	36,848	-	700,103	736,952	
	Pre Fabrication Building	12,445,429	-	12,445,429	12,445,429	-	12,445,429	-	12,445,429	12,445,429	-	123,968	-	2,355,394	2,479,362	
	Solvent Store	78,928	-	78,928	78,928	-	78,928	-	78,928	78,928	-	703	-	8,674	9,377	
<b>3</b>	<b>Plant &amp; Machinery</b>	1,322,674,143	262,098,993	1,584,773,136	1,584,773,136	-	1,584,773,136	262,098,993	1,584,773,136	1,584,773,136	262,098,993	49,341,570	481,930,562	1,102,842,573	890,085,153	
	Plant & Machinery	1,275,934,972	261,779,433	1,537,714,405	1,537,714,405	-	1,537,714,405	261,779,433	1,537,714,405	1,537,714,405	261,779,433	48,579,474	441,940,205	1,095,774,209	889,574,242	
	Electrical Installation	23,147,818	5,900	23,153,718	23,153,718	-	23,153,718	5,900	23,153,718	23,153,718	-	419,112	19,377,594	3,770,134	41,892,506	
	Generator	14,447,896	-	14,447,896	14,447,896	-	14,447,896	-	14,447,896	14,447,896	-	223,162	12,347,333	2,603,949	21,233,545	
	Gas Line Installation	3,101,333	313,650	3,414,983	3,414,983	-	3,414,983	313,650	3,414,983	3,414,983	-	1,214	2,206,929	803,920	1,814,404	
	Spare Parts	1,501,405	-	1,501,405	1,501,405	-	1,501,405	-	1,501,405	1,501,405	-	12,124	1,300,179	1,312,303	121,235	
	ETP	660,080	-	660,080	660,080	-	660,080	-	660,080	660,080	-	1,246	330,022	116,332	129,258	
	Electric Sub Station	3,889,639	-	3,889,639	3,889,639	-	3,889,639	-	3,889,639	3,889,639	-	5,312	3,882,899	47,810	53,122	
<b>4</b>	<b>Lab Equipment</b>	118,336,060	395,600	118,731,660	118,731,660	-	118,731,660	395,600	118,731,660	118,731,660	395,600	3,446,875	76,006,681	43,724,979	45,776,254	
	Lab Equipment	114,974,900	-	114,974,900	114,974,900	-	114,974,900	-	114,974,900	114,974,900	-	3,408,300	72,938,213	42,036,687	45,445,067	
	Quality Control Equipment	3,361,160	395,600	3,756,760	3,756,760	-	3,756,760	395,600	3,756,760	3,756,760	395,600	38,495	3,068,468	688,292	331,187	
<b>5</b>	<b>Furniture &amp; Fixtures</b>	62,126,502	7,331,514	69,458,016	69,458,016	-	69,458,016	7,331,514	69,458,016	69,458,016	7,331,514	2,331,941	29,001,167	40,456,850	35,457,276	
	Furniture & Fixtures	33,456,435	1,984,914	35,441,349	35,441,349	-	35,441,349	1,984,914	35,441,349	35,441,349	1,984,914	78,894	19,189,302	16,252,047	15,051,027	
	Book & Pallets	28,670,067	5,346,600	34,016,667	34,016,667	-	34,016,667	5,346,600	34,016,667	34,016,667	5,346,600	2,331,941	9,811,865	24,204,802	20,406,249	
<b>6</b>	<b>Office Equipment's</b>	47,908,015	5,165,550	52,760,784	52,760,784	-	52,760,784	5,165,550	52,760,784	52,760,784	5,165,550	1,376,490	34,313,817	18,446,963	14,774,927	
	Fire Extinguishers	1,074,615	-	1,074,615	1,074,615	-	1,074,615	-	1,074,615	1,074,615	-	9,682	955,202	119,413	129,095	
	Office Equipment's	19,319,609	198,750	19,518,359	19,518,359	-	19,518,359	198,750	19,518,359	19,518,359	198,750	41,349	14,261,325	6,257,004	5,472,183	
	Air Cooler	21,052,934	4,963,800	26,016,734	26,016,734	-	26,016,734	4,963,800	26,016,734	26,016,734	4,963,800	89,350	13,295,106	12,408,844	8,456,292	
	Coasters & Cutleries	416,096	-	416,096	416,096	-	416,096	-	416,096	416,096	-	4,681	342,166	73,930	77,821	
	Telephone Line Installation	1,192,479	3,000	1,195,479	1,195,479	-	1,195,479	3,000	1,195,479	1,195,479	3,000	14,217	1,017,247	178,232	189,459	
	Photocopier & Fax Machine	441,300	-	441,300	441,300	-	441,300	-	441,300	441,300	-	3,490	408,989	32,311	35,901	
	Projector	770,500	-	770,500	770,500	-	770,500	-	770,500	770,500	-	13,428	604,887	165,613	179,041	
	Refrigerator A/H	1,703,275	-	1,703,275	1,703,275	-	1,703,275	-	1,703,275	1,703,275	-	20,768	1,500,594	182,681	202,979	
	Mobile	1,937,208	-	1,937,208	1,937,208	-	1,937,208	-	1,937,208	1,937,208	-	3,315	1,908,271	28,935	32,150	
<b>7</b>	<b>Transport</b>	106,726,523	106,726,523	106,726,523	106,726,523	-	106,726,523	106,726,523	106,726,523	106,726,523	106,726,523	4,936,251	12,937,746	93,788,777	98,725,028	
	Vehicle	106,726,523	-	106,726,523	106,726,523	-	106,726,523	-	106,726,523	106,726,523	-	4,936,251	12,937,746	93,788,777	98,725,028	
<b>8</b>	<b>Computer &amp; IT Accessories</b>	50,322,470	4,036,210	54,358,680	54,358,680	-	54,358,680	4,036,210	54,358,680	54,358,680	4,036,210	1,691,137	39,845,025	14,513,655	12,666,582	
	Computer	40,568,759	4,036,210	44,604,969	44,604,969	-	44,604,969	4,036,210	44,604,969	44,604,969	4,036,210	1,651,235	28,879,389	14,094,370	11,689,370	
	Hardware & Networking Installation	9,753,711	-	9,753,711	9,753,711	-	9,753,711	-	9,753,711	9,753,711	-	59,902	9,334,481	419,311	478,212	
<b>9</b>	<b>Other Assets</b>	7,938,991	538,285	8,477,276	8,477,276	-	8,477,276	538,285	8,477,276	8,477,276	538,285	140,564	6,314,983	2,162,293	1,764,572	
	Sundry Assets	7,012,304	401,285	7,413,589	7,413,589	-	7,413,589	401,285	7,413,589	7,413,589	401,285	135,416	5,309,468	1,968,605	1,702,736	
	Books	926,687	137,000	1,063,687	1,063,687	-	1,063,687	137,000	1,063,687	1,063,687	137,000	5,149	864,951	193,687	61,836	
	<b>TOTAL 2023:</b>	<b>3,647,483,437</b>	<b>1,966,271,634</b>	<b>5,613,755,066</b>	<b>4,642,884,352</b>	<b>1,067,256,523</b>	<b>5,710,140,875</b>	<b>464,284,352</b>	<b>5,245,856,523</b>	<b>5,245,856,523</b>	<b>464,284,352</b>	<b>117,134,550</b>	<b>1,079,752,231</b>	<b>4,997,074,408</b>	<b>4,650,941,337</b>	
<b>10</b>	<b>Intangible Assets</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Software	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	<b>TOTAL 2024:</b>	<b>3,647,483,437</b>	<b>1,966,271,634</b>	<b>5,613,755,066</b>	<b>4,642,884,352</b>	<b>1,067,256,523</b>	<b>5,710,140,875</b>	<b>464,284,352</b>	<b>5,245,856,523</b>	<b>5,245,856,523</b>	<b>464,284,352</b>	<b>117,134,550</b>	<b>1,079,752,231</b>	<b>4,997,074,408</b>	<b>4,650,941,337</b>	
	<b>TOTAL 2024:</b>	<b>3,647,483,437</b>	<b>1,966,271,634</b>	<b>5,613,755,066</b>	<b>4,642,884,352</b>	<b>1,067,256,523</b>	<b>5,710,140,875</b>	<b>464,284,352</b>	<b>5,245,856,523</b>	<b>5,245,856,523</b>	<b>464,284,352</b>	<b>117,134,550</b>	<b>1,079,752,231</b>	<b>4,997,074,408</b>	<b>4,650,941,337</b>	
	<b>TOTAL 2024:</b>	<b>3,647,483,437</b>	<b>1,966,271,634</b>	<b>5,613,755,066</b>	<b>4,642,884,352</b>	<b>1,067,256,523</b>	<b>5,710,140,875</b>	<b>464,284,352</b>	<b>5,245,856,523</b>	<b>5,245,856,523</b>	<b>464,284,352</b>	<b>117,134,550</b>	<b>1,079,752,231</b>	<b>4,997,074,408</b>	<b>4,650,941,337</b>	

Allocation of depreciation:

Particulars	Admin	Factory	Sales & Mkt	Dist.
PPE excl Vehicle	112,198,007	4,887,920	17,951,681	-
Vehicle	4,936,251	-	4,936,251	-
<b>Total</b>	<b>117,134,258</b>	<b>4,887,920</b>	<b>22,888,332</b>	<b>-</b>







**COMPUTATION OF TOTAL INCOME AND TAX LIABILITY**  
Assessment Year 2025-26  
Income Year the period from July to Dec-2024

		Amounts in Taka
<b>NET PROFIT, BEFORE TAXATION</b>		<b>33,79,88,911</b>
- As per Profit and Loss Statement		
<u>Less: Other income -</u>		
Cash incentive	1,19,64,386	
Bank interest	3,05,240	
Interest on FDR	4,65,825	
Dividend income	901,146	
Sale of wastage	23,05,190	
Gain on disposal of FA	-74,523	
Realized Gain/(loss) on Share Sell	-10,457,145	
PF Forfeiture	12,10,459	
		<b>66,20,578</b>
		<b>33,13,68,333</b>
 <b>ADDITIONS FOR SUBSEQUENT/ SEPERATE CONSIDERATIONS</b>		
<u>Add: Accounting depreciation</u>	13,32,42,459	
- Depreciation on ROUA	1,631,563	
- Entertainment	15,33,363	
- Incentive	3,13,97,374	
- Sample expenses	2,78,43,281	
- Gratuity provision	3,27,50,000	
- Broken/ damaged provision	19,96,636	
- Promotional Expense	2,84,66,788	
- Bad debt provision	66,45,483	
- Foreign tour	62,43,231	
		<b>27,17,50,178</b>
		<b>60,31,18,511</b>
 <b>ADJUSTMENTS FOR STATUTORY DISALLOWANCES</b>		
<u>Less: Depreciation as per Income Tax Act 2023</u>		<b>133,242,459</b>
<u>Less: Rent of ROUA</u>		<b>1,631,563</b>
		<b>46,82,44,489</b>
 <u>Less: Sample expenses</u>		
Total turnover	4,363,718,011	
On first 5 crore @ 2%	1,000,000	
On Next 5 crore @ 1%	500,000	
Balance @ 0.5%	21,318,590	
<b>Allowable</b>	<b>22,818,590</b>	<b>2,28,18,590</b>
		<b>44,54,25,899</b>
 <u>Less: Gratuity paid</u>	57,50,000	
Bad debt written off	1,46,80,203	
Incentive @10% of Profit	3,37,98,891	
Promotional Expense @0.5% of Turnover	2,18,18,590	
Foreign tour @ 0.5% of disclosed turnover u/s 30(k) of ITO 1984 or the actual expenditure, whichever is less.	62,43,231	
		<b>8,22,90,915</b>
		<b>36,31,34,984</b>
 <u>Less: Entertainment allowance permissible as per rule 65 of Income Tax Rules 1984, on profit before tax claim of entertainment allowance @4% on the first Taka 10,00,000 of income at @ 2% on the balance income. The lower amount is allowed, as permissible.</u>		<b>15,33,363</b>
		<b>36,16,01,621</b>
 <u>Less:</u>		
Export sale @ 7%		<b>1,82,93,623</b>
<b>INCOME FROM LOCAL BUSINESS</b>		<b>34,33,07,998</b>
<b>INCOME FROM EXPORT BUSINESS</b>		<b>1,82,93,623</b>
<b>CAPITAL Gain -disposal of FA</b>		<b>36,16,01,621</b>
	<b>Total</b>	<b>36,16,01,621</b>
 <u>Add: Other income -</u>		
Cash incentive	1,19,64,386	
Bank interest	3,05,240	
Sale of wastage	23,05,190	
Dividend Income	9,01,146	
Interest on FDR	4,65,825	
PF Forfeiture	12,10,459	
Realized Gain from Share Sale	-10,457,145	
		<b>66,95,101</b>
		<b>36,82,96,722</b>
 <b>TOTAL INCOME</b>		<b>36,82,96,722</b>



**COMPUTATION OF TOTAL INCOME AND TAX LIABILITY**  
 Assessment Year 2025-26  
 Income Year the period from July to Dec-2024

Calculation of minimum tax

(i) (a) On business income @ 22.5%	1,12,44,300		
(b) On other income excluding Capital Gain @ 22.5%	7,91,021	7,80,35,321	}
(ii) On turnover of Taka 4,363,718,011 @ 0.60%		2,61,82,308	
Minimum tax -- higher of (i) and (ii)			7,80,35,321

Calculation of tax on export income

(i) Tax at regular rate @12.5%		22,86,703	
Less: Rebate @ 50% (under paragraph 28 of Part A of the Sixth Schedule)		11,43,351	}
(ii) Tax deducted at source		25,21,328	
Minimum tax -- higher of (i) and (ii)			25,21,328

Calculation tax on PF:

Capital gain on share disposal tax thereon 22.5%		272,353	2,72,353
--	--	---------	----------

Calculation tax on Cash Incentive:

Cash Incentive tax thereon 22.5%		2,691,987	26,91,987
----------------------------------	--	-----------	-----------

Calculation tax on Cash Incentive:

FDR Interest tax thereon 22.5%		104,811	1,04,811
--------------------------------	--	---------	----------

Calculation tax on Sales of Wastage:

Sales of Wastage tax thereon 22.5%		518,668	5,18,668
------------------------------------	--	---------	----------

Calculation tax on Bank Interest:

Bank Interest tax thereon 22.5%		68,679	68,679
---------------------------------	--	--------	--------

Calculation tax on Dividend:

Dividend tax thereon 20%		90,115	90,115
--------------------------	--	--------	--------

**Total Tax Liability**

**84,303,261**



